Contact Us
  Search
The Business Research Company Logo

Crohn's Disease (CD) Treatment Market Report 2026

Buy Now
Global Crohn's Disease (CD) Treatment Market Report 2026
Published :January 2026
Pages :150
Format :PDF
Delivery Time :2-3 Business Days
Why 2-3 days? We update the report with the latest data and news before delivery. Let us know if you need us to expedite.
Report Price :$4,490.00

Crohn's Disease (CD) Treatment Market Report 2026

Global Outlook – By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types), By Route Of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) - Market Size, Trends, And Global Forecast 2026-2035

Crohn's Disease (CD) Treatment Market Overview

• Crohn's Disease (CD) Treatment market size has reached to $12.32 billion in 2025 • Expected to grow to $16.01 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Increasing Prevalence Of Inflammatory Bowel Diseases Fuels Growth In The Crohn’S Disease Treatment Market • Market Trend: Innovative Diagnostic Technologies Enhance Non-Invasive Detection And Disease Monitoring In The Market • North America was the largest region in 2025.
Research Expert

Book your 30 minutes free consultation with our research experts

What Is Covered Under Crohn's Disease (CD) Treatment Market?

Crohn's disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn's disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition. The main drug types of crohn's diseases treatment are antibiotics, amino salicylates, corticosteroids, immunomodulators, and other drug types. Antibiotics are medicines that fight bacterial infections in people and animals by killing the bacteria or making it hard for them to grow and multiply. The route of administration includes oral and injectable, which are distributed to through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.
Crohn's Disease (CD) Treatment Market Global Report 2026 Market Report bar graph

What Is The Crohn's Disease (CD) Treatment Market Size and Share 2026?

The crohn's disease (cd) treatment market size has grown steadily in recent years. It will grow from $12.32 billion in 2025 to $12.88 billion in 2026 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increasing inflammatory bowel disease prevalence, limitations of conventional corticosteroids, hospital-centered disease management, delayed diagnosis rates, reliance on immunomodulators.

What Is The Crohn's Disease (CD) Treatment Market Growth Forecast?

The crohn's disease (cd) treatment market size is expected to see strong growth in the next few years. It will grow to $16.01 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in biologics development, growth of precision medicine, expanding patient awareness, improved diagnostic techniques, increased specialty gastroenterology care. Major trends in the forecast period include rising use of biologic therapies, expansion of targeted small molecule drugs, increased focus on long-term disease remission, growth of personalized treatment approaches, integration of combination therapy regimens.

Global Crohn's Disease (CD) Treatment Market Segmentation

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types 2) By Route Of Administration: Oral, Injectable 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores Subsegments: 1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin 2) By Amino Salicylates: Mesalamine, Sulfasalazine 3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone 4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate 5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

What Is The Driver Of The Crohn's Disease (CD) Treatment Market?

The increasing prevalence of inflammatory bowel diseases is expected to propel the growth of the Crohn’s disease (CD) treatment market going forward. Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders primarily affecting the gastrointestinal (GI) tract. Crohn’s disease (CD) treatment offers relief from symptoms, reduces inflammation, promotes remission and enhances the overall quality of life for individuals suffering from chronic inflammatory bowel disease. For instance, in September 2023, the United States National Library of Medicine, a US-based medical library, estimated that in Canada, the incidence of inflammatory bowel diseases (IBD) was estimated at 30 per 100,000 person years in 2023, with projections indicating a steady increase of approximately 0.58% per year. As of 2023, the prevalence of IBD in Canada reached about 825 per 100,000, with forecasts suggesting that this could rise to 1.1% of the population by 2035. Therefore, the increasing prevalence of inflammatory bowel diseases drives the Crohn’s disease (CD) treatment market.

Key Players In The Global Crohn's Disease (CD) Treatment Market

Major companies operating in the crohn's disease (cd) treatment market are AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann‑La Roche

What Are Latest Mergers And Acquisitions In The Crohn's Disease (CD) Treatment Market?

In June 2023, Merck & Co. Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.8 billion. With this acquisition, Merck & Co. aims to expand its product portfolio in immunological and inflammatory condition treatment drugs. Prometheus Biosciences is a US-based biotechnology company involved in developing inflammatory disease drugs and has expertise in Crohn’s disease and inflammatory bowel disease treatments.

Regional Outlook

North America was the largest region in the Crohn’s disease (CD) treatment market in 2025. The regions covered in the crohn's disease (cd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crohn's disease (cd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Need data on a specific region in this market?

What Defines the Crohn's Disease (CD) Treatment Market?

The Crohn's disease (CD) treatment market consists of sales of Janus kinase inhibitors and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Crohn's Disease (CD) Treatment Market Report 2026?

The crohn's disease (cd) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the crohn's disease (cd) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Crohn's Disease (CD) Treatment Market Report Forecast Analysis

Report Attribute Details
Market Size Value In 2026$12.88 billion
Revenue Forecast In 2035$16.01 billion
Growth RateCAGR of 4.5% from 2026 to 2035
Base Year For Estimation2025
Actual Estimates/Historical Data2020-2025
Forecast Period2026 - 2030 - 2035
Market RepresentationRevenue in USD Billion and CAGR from 2026 to 2035
Segments CoveredDrug Type, Route Of Administration, Distribution Channel
Regional ScopeAsia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country ScopeThe countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies ProfiledAbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann‑La Roche
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Frequently Asked Questions

The Crohn's Disease (CD) Treatment market was valued at $12.32 billion in 2025, increased to $12.88 billion in 2026, and is projected to reach $16.01 billion by 2030.
request a sample here
The global Crohn's Disease (CD) Treatment market is expected to grow at a CAGR of 5.6% from 2026 to 2035 to reach $16.01 billion by 2035.
request a sample here
Some Key Players in the Crohn's Disease (CD) Treatment market Include, AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann‑La Roche .
request a sample here
Major trend in this market includes: Innovative Diagnostic Technologies Enhance Non-Invasive Detection And Disease Monitoring In The Market. For further insights on this market.
request a sample here
North America was the largest region in the Crohn’s disease (CD) treatment market in 2025. The regions covered in the crohn's disease (cd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
request a sample here
Research Expert

Book your 30 minutes free consultation with our research experts

Chat with us